Coronation Fund Managers Ltd. Has $29.55 Million Stock Position in Thermo Fisher Scientific Inc. $TMO

Key Points

• Coronation Fund Managers reduced its Thermo Fisher stake by 31.7% in Q4 to 50,995 shares worth $29.55 million, making TMO its 21st-largest holding and 1.3% of the fund's portfolio.
• Thermo Fisher beat Q1 expectations with $5.44 EPS vs. ~$5.25 consensus and $11.01 billion revenue (up ~6.2% y/y), and management raised FY2026 guidance to $24.64–$25.12 EPS.
• The company raised its quarterly dividend to $0.47 ($1.88 annualized) for a ~0.4% yield, while maintaining a low dividend payout ratio of about 10%.

Coronation Fund Managers Ltd. decreased its position in Thermo Fisher Scientific Inc. (NYSE:TMO - Free Report) by 31.7% in the 4th quarter, according to its most recent filing with the Securities & Exchange Commission. The firm owned 50,995 shares of the medical research company's stock after selling 23,652 shares during the period. Thermo Fisher Scientific makes up 1.3% of Coronation Fund Managers Ltd.'s portfolio, making the stock its 21st largest position. Coronation Fund Managers Ltd.'s holdings in Thermo Fisher Scientific were worth $29,549,000 at the end of the most recent quarter.

A number of other hedge funds also recently modified their holdings of the business. Munich Reinsurance Co Stock Corp in Munich raised its position in shares of Thermo Fisher Scientific by 60.1% during the fourth quarter. Munich Reinsurance Co Stock Corp in Munich now owns 62,250 shares of the medical research company's stock worth $36,320,000 after purchasing an additional 23,375 shares during the period. Riverbend Wealth Management LLC grew its position in shares of Thermo Fisher Scientific by 6.6% in the 4th quarter. Riverbend Wealth Management LLC now owns 806 shares of the medical research company's stock valued at $467,000 after purchasing an additional 50 shares during the period. Approach Retirement Advisors LLC acquired a new position in shares of Thermo Fisher Scientific in the 4th quarter valued at approximately $377,000. Klingman & Associates LLC grew its position in shares of Thermo Fisher Scientific by 1.6% in the 4th quarter. Klingman & Associates LLC now owns 1,879 shares of the medical research company's stock valued at $1,089,000 after purchasing an additional 30 shares during the period. Finally, Dunhill Financial LLC grew its position in shares of Thermo Fisher Scientific by 679.8% in the 4th quarter. Dunhill Financial LLC now owns 772 shares of the medical research company's stock valued at $447,000 after purchasing an additional 673 shares during the period. Institutional investors and hedge funds own 89.23% of the company's stock.

Thermo Fisher Scientific Trading Up 0.6%

Thermo Fisher Scientific stock opened at $469.27 on Friday. The firm has a 50-day moving average of $499.11 and a 200-day moving average of $549.45. Thermo Fisher Scientific Inc. has a one year low of $385.46 and a one year high of $643.99. The company has a debt-to-equity ratio of 0.77, a current ratio of 1.53 and a quick ratio of 1.53. The company has a market cap of $174.39 billion, a price-to-earnings ratio of 25.80, a P/E/G ratio of 2.41 and a beta of 0.97.

Thermo Fisher Scientific (NYSE:TMO - Get Free Report) last posted its quarterly earnings data on Thursday, April 23rd. The medical research company reported $5.44 EPS for the quarter, topping analysts' consensus estimates of $5.25 by $0.19. Thermo Fisher Scientific had a net margin of 15.15% and a return on equity of 16.86%. The company had revenue of $11.01 billion during the quarter, compared to the consensus estimate of $10.86 billion. During the same period in the prior year, the business posted $5.15 EPS. The company's quarterly revenue was up 6.2% on a year-over-year basis. Thermo Fisher Scientific has set its FY 2026 guidance at 24.640-25.120 EPS. On average, equities analysts expect that Thermo Fisher Scientific Inc. will post 24.71 earnings per share for the current fiscal year.

Thermo Fisher Scientific Increases Dividend

The firm also recently disclosed a quarterly dividend, which was paid on Wednesday, April 15th. Stockholders of record on Friday, March 13th were paid a dividend of $0.47 per share. The ex-dividend date was Friday, March 13th. This represents a $1.88 dividend on an annualized basis and a dividend yield of 0.4%. This is a positive change from Thermo Fisher Scientific's previous quarterly dividend of $0.43. Thermo Fisher Scientific's dividend payout ratio (DPR) is currently 10.34%.

Key Thermo Fisher Scientific News

Here are the key news stories impacting Thermo Fisher Scientific this week:

• Positive Sentiment: Q1 results beat expectations — Thermo Fisher reported $5.44 adjusted EPS vs. ~$5.25 consensus and revenue of $11.01B (up ~6.2% y/y), showing the company still delivered above-street top- and bottom-line results. Reuters: Thermo Fisher posts quarterly results beat
• Positive Sentiment: Full-year guidance updated — Management set FY2026 EPS guidance of $24.64–$25.12 and raised its outlook, which supports longer-term earnings visibility even if organic growth is uneven. Yahoo: Thermo Fisher Raises 2026 Outlook
• Neutral Sentiment: Analyst reactions mixed but generally constructive — Several firms kept buy/outperform ratings while trimming targets (Stifel: $700->$600; Robert W. Baird: $653->$639), signaling continued confidence in the company’s fundamentals despite the pullback. Benzinga / The Fly: PT cuts
• Neutral Sentiment: Analyst voices emphasize long-term opportunity — Some analysts (e.g., TD Cowen, William Blair) reiterated Buy ratings, pointing to core growth drivers and structural demand (biopharma services, lab products) that support recovery later in the year. TipRanks: Analyst commentary
• Negative Sentiment: Market punished the stock on weak underlying growth and mixed segments — Despite the beat, investors focused on muted organic growth in the core business and uneven segment performance, which triggered a sharp intraday decline and premarket weakness. Yahoo: Why TMO Stock Is Nosediving
• Negative Sentiment: Broader sector & market pressure amplified the move — The mixed report pressured peers (e.g., 10x Genomics) and coincided with a softer tape for health care/tech stocks, adding to downward momentum. Yahoo: Peer impact (10x Genomics)

Wall Street Analysts Forecast Growth

TMO has been the subject of a number of research analyst reports. Weiss Ratings reaffirmed a "hold (c)" rating on shares of Thermo Fisher Scientific in a research note on Wednesday, April 8th. Evercore reaffirmed an "outperform" rating and issued a $650.00 target price on shares of Thermo Fisher Scientific in a research note on Monday, January 5th. DZ Bank began coverage on shares of Thermo Fisher Scientific in a research note on Friday, March 27th. They issued a "buy" rating and a $610.00 target price for the company. Wells Fargo & Company set a $683.00 target price on shares of Thermo Fisher Scientific in a research note on Friday, January 30th. Finally, UBS Group reaffirmed a "neutral" rating and issued a $615.00 target price on shares of Thermo Fisher Scientific in a research note on Friday, January 30th. One analyst has rated the stock with a Strong Buy rating, nineteen have assigned a Buy rating and two have assigned a Hold rating to the company's stock. Based on data from MarketBeat.com, the company currently has a consensus rating of "Moderate Buy" and a consensus target price of $625.55.

Insider Transactions at Thermo Fisher Scientific

In other news, CEO Marc N. Casper sold 5,000 shares of the stock in a transaction dated Wednesday, March 4th. The shares were sold at an average price of $512.40, for a total transaction of $2,562,000.00. Following the completion of the transaction, the chief executive officer directly owned 123,925 shares in the company, valued at $63,499,170. This represents a 3.88% decrease in their position. The transaction was disclosed in a filing with the SEC, which is available at the SEC website. Also, EVP Gianluca Pettiti sold 400 shares of the stock in a transaction dated Monday, February 9th. The stock was sold at an average price of $541.20, for a total transaction of $216,480.00. Following the transaction, the executive vice president owned 20,752 shares of the company's stock, valued at approximately $11,230,982.40. This represents a 1.89% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. Corporate insiders own 0.33% of the company's stock.

About Thermo Fisher Scientific

Thermo Fisher Scientific NYSE: TMO is a global provider of scientific instrumentation, reagents and consumables, software, and services that support research, clinical, and industrial laboratories. The company supplies analytical instruments and laboratory equipment, life sciences reagents and kits, specialty diagnostics, and a broad range of consumables used by researchers, clinicians, and manufacturers. Its offerings also include laboratory information management and data-analysis software, as well as service solutions such as instrument maintenance, validation, and logistics that help customers run complex workflows efficiently.

Thermo Fisher operates through multiple business areas that broadly cover life sciences solutions, analytical instruments, specialty diagnostics, and laboratory products and biopharma services, including contract development and manufacturing for pharmaceutical and biotechnology companies.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.